Geode Capital Management LLC Boosts Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Geode Capital Management LLC boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 0.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,771,831 shares of the company's stock after purchasing an additional 26,727 shares during the period. Geode Capital Management LLC owned about 1.07% of Roivant Sciences worth $91,968,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ROIV. Norges Bank bought a new position in shares of Roivant Sciences in the fourth quarter worth $52,443,000. Vanguard Group Inc. boosted its position in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the period. State Street Corp grew its stake in Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after acquiring an additional 1,118,561 shares in the last quarter. Pertento Partners LLP lifted its stake in Roivant Sciences by 22.8% in the 4th quarter. Pertento Partners LLP now owns 3,484,918 shares of the company's stock worth $41,227,000 after purchasing an additional 646,865 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Roivant Sciences by 17.4% during the fourth quarter. Bank of New York Mellon Corp now owns 3,439,540 shares of the company's stock valued at $40,690,000 after buying an additional 510,398 shares during the period. Institutional investors own 64.76% of the company's stock.

Insider Buying and Selling

In other news, COO Eric Venker sold 218,041 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the sale, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at approximately $9,345,374.98. This represents a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,395,541 shares of company stock valued at $15,028,538 over the last quarter. 7.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th.

Roivant Sciences Stock Performance

ROIV traded down $0.05 on Wednesday, hitting $10.02. 430,563 shares of the company were exchanged, compared to its average volume of 5,389,680. The stock has a market capitalization of $7.15 billion, a PE ratio of -66.88 and a beta of 1.25. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06. The firm has a fifty day simple moving average of $10.37 and a two-hundred day simple moving average of $11.20.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.